#USA #Seattle #Clinical Trials #Atossa Therapeutics #Z-Endoxifen

Atossa Therapeutics Triumphs with 2025 Excellence Award

Atossa Therapeutics, Inc. (NASDAQ: ATOS), a leading clinical-stage biopharmaceutical company, has earned the prestigious 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy category. This accolade recognizes Atossa’s innovative progress in developing (Z)-Endoxifen, a precision-engineered therapy that promises to revolutionize treatment in oncology and other critical medical fields.

Achievements in Precision Endocrine Therapy

The recognition given to Atossa Therapeutics underscores the company’s commitment to addressing unmet medical needs. Atossa’s leading therapy, (Z)-Endoxifen, is a potent selective estrogen receptor modulator and degrader (SERM/D) which is distinct due to its unique pharmacological profile. This innovative therapy aims to provide consistent systemic exposure, bypassing the individual variations caused by CYP2D6 metabolism, a common challenge in medication efficacy.

Atossa is currently exploring (Z)-Endoxifen’s application not only in multiple breast cancer settings but also in born out of the company’s ongoing investigation into rare diseases, such as Duchenne Muscular Dystrophy (DMD).

Steven Quay, M.D., Ph.D., President and CEO of Atossa Therapeutics, stated, “This award highlights our team's commitment to precision endocrine therapy and our integrated approach to developing (Z)-Endoxifen for patients with high unmet medical needs. By combining biomarker-driven clinical studies, adaptive trial designs, and proactive regulatory engagement, we are advancing a therapy that has the potential to make a meaningful impact across multiple patient populations.”

The Clinical Trials Arena Excellence Awards

The Clinical Trials Arena Excellence Awards, powered by GlobalData’s extensive data analysis, are designed to honor organizations demonstrating exceptional scientific rigor, innovation, and leadership in the drug development and clinical research fields. Atossa’s selection was the result of a comprehensive evaluation involving over a billion datasets, showcasing its outstanding performance in the life sciences industry.

(Z)-Endoxifen: A Promising Future

(Z)-Endoxifen is characterized by its multifaceted mechanisms, already showing promise in diverse therapeutic areas. Unlike tamoxifen, Atossa's proprietary oral formulation has exhibited a favorable safety profile, indicating a differentiated approach to targeting estrogen-related issues. Importantly, (Z)-Endoxifen is still awaiting regulatory approval, and Atossa continues to build a robust intellectual property portfolio to protect its findings and innovations globally.

Beyond the cancer treatment landscape, the company’s foray into addressing rare diseases signifies its ambition to broaden the scope and impact of (Z)-Endoxifen, potentially reshaping treatment protocols.

Atossa’s ongoing commitment to disciplined capital allocation ensures that resources are effectively directed to support clinical trials, paving the way for future regulatory submissions and market introductions.

Conclusion

Atossa Therapeutics is at the forefront of biopharmaceutical innovation, exemplified by its recent Excellence Award. With a focus on groundbreaking therapies like (Z)-Endoxifen, the company is setting new standards in the field of medicine, striving to meet the needs of patients who face limited treatment options. As clinical trials advance and new indications emerge, Atossa is poised to make a significant difference in the health care landscape.

To learn more about (Z)-Endoxifen and Atossa's initiatives, please visit Atossa Therapeutics.